Workflow
Tigermed(300347)
icon
Search documents
创新药,大跌
中国基金报· 2025-09-11 01:49
Market Overview - On September 11, the Shanghai Composite Index opened down 0.16%, while the ChiNext Index rose by 0.46% [1] - Pharmaceutical stocks experienced significant declines, with companies like BeiGene, WuXi AppTec, and Tigermed opening down over 7% [1] - Over 4,400 stocks were down, with innovative drug concept stocks like BeiGene and Tigermed seeing declines exceeding 10% [1] Index Performance - The Sci-Tech 50 Index stood at 1247.69, down 0.91% [3] - The ChiNext Index was at 2907.80, up 0.12% [3] - The CSI 300 Index was at 4432.68, down 0.29% [3] - The total number of stocks that declined in the Wande All A Index was 4456, while 870 stocks rose [3] Pharmaceutical Sector Performance - The innovative drug index fell by 4.08%, with a net outflow of 17.83 billion [4] - Major pharmaceutical companies like BeiGene and Tigermed saw declines of 10.57% and 10.68%, respectively [5][6] - Other pharmaceutical indices, such as monoclonal antibody and generic drug indices, also reported declines of 4.05% and 3.71% [4] Notable Stock Movements - BeiGene (688235) traded at 283.50, down 10.57% with a market cap of 12.604 billion [5] - Tigermed (300347) traded at 57.36, down 10.68% with a market cap of 147.2 billion [6] - Kanglong Chemical (300759) traded at 30.36, down 7.72% with a market cap of 50%Z [7] Additional Pharmaceutical Stocks - Other notable declines included companies like Aopumai, Bidu Pharmaceutical, and Kailai Ying, with declines ranging from 5.91% to 6.30% [9]
A股早评:创业板指高开0.46%,算力硬件概念股活跃!青山纸业8天5板,东山精密、中际旭创涨超4%,新诺威、泰格医药跌超10%
Ge Long Hui· 2025-09-11 01:47
Market Overview - The A-share market opened with mixed performance among the three major indices, with the Shanghai Composite Index down by 0.16%, the Shenzhen Component Index up by 0.11%, and the ChiNext Index up by 0.46% [1] Sector Performance - The computing power hardware sector, including CPO and liquid-cooled servers, showed significant activity, with companies like Qingshan Paper (600103) achieving five consecutive trading limits in eight days, and Dongshan Precision (002384) and Zhongji Xuchuang (300308) rising over 4% [1] - OpenAI and Oracle signed a substantial computing power deal worth $300 billion, indicating strong demand in the sector [1] Pharmaceutical Sector - The pharmaceutical sector opened lower, with companies such as XinNuoWei (300765) and Tigermed (300347) experiencing declines of over 10% [1] Film and Entertainment Sector - The film and cinema sector also opened lower, with companies like Happiness Blue Sea (300528) and Huanrui Century (000892) dropping over 10% and 4% respectively [1]
创新药概念股大幅低开
第一财经· 2025-09-11 01:43
Market Overview - The innovative drug concept stocks opened significantly lower, with BeiGene dropping over 10%, WuXi AppTec and Tigermed down over 7%, and several other companies like HengRui Medicine, Junshi Biosciences, and Kelun Pharmaceutical falling over 5% [3][4]. - The A-share market showed mixed results, with the Shanghai Composite Index down 0.16%, while the Shenzhen Component Index rose 0.11% and the ChiNext Index increased by 0.46% [4][5]. Sector Performance - The healthcare sector experienced a decline, with various sub-sectors such as medical services, CRO concepts, and innovative drugs all showing negative performance, with declines ranging from -1.99% to -1.44% [6]. - The Hong Kong market also opened lower, with the Hang Seng Index down 0.81% and the Hang Seng Tech Index falling 0.97%. Pharmaceutical stocks in Hong Kong saw significant drops, with companies like Hansoh Pharmaceutical and WuXi Biologics declining over 10% [6][7]. Notable Stocks - Specific stocks highlighted include BeiGene, WuXi AppTec, and Tigermed, which are part of the innovative drug sector and faced substantial declines in their stock prices [3][4]. - In the Hong Kong market, Hansoh Pharmaceutical and WuXi Biologics were noted for their significant drops, while a few stocks like Jiujiuwang Technology showed resilience with a 5% increase [6][7].
A股CRO概念多股低开,药明康德、泰格医药跌超7%
Mei Ri Jing Ji Xin Wen· 2025-09-11 01:41
Group 1 - The A-share CRO sector experienced a decline, with major companies like WuXi AppTec and Tigermed dropping over 7% [1] - Kanglong Chemical fell by more than 5%, while other firms such as Zhaoyan New Drug, Mediso, and Hengrui Medicine also saw declines [1]
滚动更新丨A股三大指数开盘涨跌不一,创新药概念股大幅低开
Di Yi Cai Jing· 2025-09-11 01:34
Market Overview - The pharmaceutical sector experienced significant declines, with WuXi AppTec and Tigermed opening down over 7% [1][2] - Innovative drug concept stocks also saw substantial drops, with BeiGene falling over 10% and several other companies, including WuXi AppTec and Tigermed, dropping more than 7% [1][2] Index Performance - The Shanghai Composite Index decreased by 0.16%, while the Shenzhen Component Index increased by 0.11%, and the ChiNext Index rose by 0.46% [2][3] - The healthcare services sector fell by 1.99%, with various sub-sectors such as weight loss drugs and CRO concepts also declining [3] Hong Kong Market - The Hang Seng Index opened down 0.81%, and the Hang Seng Tech Index fell by 0.97% [4][5] - Pharmaceutical stocks in Hong Kong saw widespread declines, with Hansoh Pharmaceutical and WuXi Biologics dropping over 10% [4] Currency and Monetary Policy - The People's Bank of China conducted a 7-day reverse repurchase operation of 292 billion yuan at a steady rate of 1.40% [5] - The RMB to USD central parity rate was reported at 7.1034, an increase of 28 basis points from the previous trading day [6]
2025中报分析之CRO、CDMO:轻舟已过万重山,再举云帆万里程,积极把握新一轮产业周期
ZHONGTAI SECURITIES· 2025-09-10 10:51
Investment Rating - The report maintains a rating of "Buy" for key companies in the CRO and CDMO sectors, including WuXi AppTec, WuXi Biologics, and others [4][12]. Core Insights - The report indicates that the current industry cycle is expected to continue, driven by improved global liquidity, recovering overseas demand, and technological breakthroughs in areas such as XDC, peptides, and oligonucleotides [6][19]. - In the first half of 2025, the CRO and CDMO sectors showed significant revenue growth, with a 10.4% increase in revenue and a 73.2% increase in net profit attributable to shareholders [6][30]. - The report highlights a divergence in performance between CDMO and CRO, with CDMO experiencing rapid growth while CRO faces slight pressure [6][23]. Summary by Sections Revenue and Profit - In the first half of 2025, the CRO and CDMO sectors achieved a total revenue of 709.1 billion yuan, reflecting a 10.4% year-on-year increase [21]. - The net profit attributable to shareholders reached 151.4 billion yuan, up 73.2%, while the adjusted Non-IFRS net profit was approximately 165.8 billion yuan, marking an 84.8% increase [30][35]. Key Indicators - Demand recovery is evident, with significant increases in orders for major companies such as WuXi AppTec, which reported a 37.2% year-on-year increase in orders [7][37]. - The report notes that the CDMO sector's revenue reached approximately 320.8 billion yuan, a 40.8% increase, while CRO revenue was about 235.9 billion yuan, down 3.5% [23][30]. Focus Companies - The report identifies 30 key companies in the CRO and CDMO sectors, including WuXi AppTec, WuXi Biologics, and others, which are expected to benefit from ongoing industry trends [12][19]. - Specific companies like WuXi Biologics and WuXi AppTec are highlighted for their strong order backlogs and growth potential [38]. Investment Recommendations - The report suggests focusing on CDMO companies due to their expected growth driven by technological advancements and increasing demand for commercialized products [8][19]. - For CRO companies, the report anticipates a gradual recovery as the investment environment improves and orders stabilize [8][19].
泰格医药跌2.02%,成交额2.13亿元,主力资金净流出490.10万元
Xin Lang Cai Jing· 2025-09-09 03:16
Company Overview - Tiger Med is located in Hangzhou, Zhejiang Province, and was established on December 15, 2004, with its IPO on August 17, 2012 [1] - The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products, covering I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has cumulatively distributed 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3] Stock Performance - As of September 9, Tiger Med's stock price was 65.83 yuan per share, with a market capitalization of 56.681 billion yuan [1] - Year-to-date, the stock price has increased by 21.18%, but it has seen a decline of 0.63% over the last five trading days and 1.78% over the last twenty days [1] Shareholder Information - As of June 30, 2025, the number of shareholders was 51,500, a decrease of 4.14% from the previous period [2] - The top ten circulating shareholders include notable funds, with changes in their holdings indicating varying levels of investment interest [3]
泰格医药:9月29日将召开2025年第一次临时股东会
Zheng Quan Ri Bao· 2025-09-08 12:11
Group 1 - The company, Tigermed, announced that it will hold its first extraordinary general meeting of shareholders for 2025 on September 29, 2025 [2] - The meeting will review multiple proposals, including the proposal for amendments [2]
泰格医药(300347) - 关于召开2025年第一次临时股东会的公告
2025-09-08 09:30
证券代码:300347 证券简称:泰格医药 公告编码(2025)037 号 杭州泰格医药科技股份有限公司 关于召开 2025 年第一次临时股东会的公告 公司及董事会全体成员保证公告内容的真实、准确和完整,对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 一、召开会议的基本情况 1.股东会届次:2025年第一次临时股东会。 2.股东会的召集人:公司董事会。 3.会议召开的合法、合规性:经公司第五届董事会第十八次会议审议通过,决定召 开2025年第一次临时股东会,召集程序符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 4.会议召开的日期、时间: 现场会议召开日期和时间:2025 年9 月29 日(星期一)下午15:00 网络投票日期和时间: (1)通过深圳证券交易所交易系统进行网络投票的时间为:2025 年 9 月 29 日上午 9:15—9:25,9:30—11:30 和下午13:00-15:00; (2)通过深圳证券交易所互联网投票系统投票的具体时间为:2025 年9 月29 日上午 9:15 至2025 年9 月29 日下午15:00。 5.会议的召开方式:本次股东会采用现场表决与网 ...
泰格医药(03347) - 2025年9月29日(星期一)举行的2025年第一次临时股东大会代表委任...
2025-09-08 08:33
杭州泰格醫藥科技股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:3347) 2025年9月29日(星期一)舉行的2025年第一次臨時股東大會代表委任表格 本人╱ 吾等 1 地址為 為杭州泰格醫藥科技股份有限公司(「本公司」)股本中每股面值人民幣1.00元股份 股 2 H股登記持有人,茲委任大會主席 3 或 地址為 HANGZHOU TIGERMED CONSULTING CO., LTD. 日期:2025年 月 日 簽署 5 : 附註: 收集個人資料聲明 本代表委任表格所指的「個人資料」具有《個人資料(私隱)條例》(第486章)(「私隱條例」)賦予「個人資料」之相同 涵義,當中包括 閣下及 閣下代表的姓名及地址。 為本人╱ 吾等的受委代表,代表本人╱ 吾等出席本公司謹訂於2025年9月29日(星期一)下午 三時正假座中國杭州市濱江區聚工路19號盛大科技園A座18樓會議室舉行2025年第一次臨 時股東大會(「臨時股東大會」)及其任何續會,以考慮及酌情通過載於臨時股東大會通告的 決議案,並於臨時股東大會及其任何續會代表本人╱ 吾等並以本人╱ 吾等名義就下述決議 案按以下方式投票。除非另有說明 ...